Dx M&A Deals Decline as Industry Returns to Normal Post-COVID Boom
Article By Kelsy Ketchum / January 8, 2024
The diagnostics industry has finally completed its return to normal after three years of heavier dealmaking, as full-company mergers and acquisitions declined to pre-COVID-19 levels in 2023.
News
Leaders of Life Sciences – How Leadership Must Evolve As Companies Scale
In this conversation, Stan Glazer, Managing Director at Outcome, shares insights from his extensive experience in the life sciences industry.
Read MoreResources
Outcome Capital Life Science Market Pulse, April 2025
Outcome Capital Life Science Market Pulse April 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
